Executive Summary
Most biotechnology companies believe their greatest risk is clinical failure.
In reality, many significantly reduce shareholder value long before a Phase III trial fails.
They overestimate market opportunity, build organizations that exceed commercial demand, and commit fixed costs that future revenue cannot support.
Marinus Pharmaceuticals provides an important case study. The company ultimately faced multiple challenges, including clinical setbacks, financing pressures, and commercial realities. This article does not suggest commercialization alone determined the company's outcome. Rather, it examines the commercial decisions that offer broader lessons for biotechnology leaders.
Like many biotechnology companies, Marinus pursued an important mission to improve the lives of patients with devastating neurological disorders. The purpose of this discussion is not to criticize that mission, but to examine strategic decisions from which other biotechnology companies can learn.
Every Rare Disease Company Starts with Optimism
When Ztalmy® (ganaxolone) received FDA approval for CDKL5 Deficiency Disorder (CDD), expectations were understandably high.
The commercial narrative included:
- Strong physician adoption
- Significant patient demand
- Rapid reimbursement
- Pipeline expansion
- Long-term growth
Many rare disease companies begin with similar assumptions.
The challenge is that commercial reality rarely follows forecast models.
Patient Population Does Not Equal Commercial Opportunity
One of the most common mistakes biotechnology companies make is confusing disease prevalence with an immediately addressable commercial market.
Published prevalence estimates may identify hundreds of patients living with a disease, but not every patient is diagnosed, actively treated, clinically appropriate, insured, geographically accessible, or ready to initiate therapy during the first years following launch.
Based on my commercial assessment of diagnosis patterns, treatment eligibility, physician adoption, and launch dynamics, I believed the immediately addressable patient population was substantially smaller than commonly assumed by many commercial forecasts. Whether the number was 50 patients, 100 patients, or somewhat higher is less important than the broader lesson.
Commercial organizations should be built around treated patients—not theoretical patients.
That distinction can fundamentally change hiring plans, revenue expectations, manufacturing requirements, and capital allocation.
Building Too Much Infrastructure Too Soon
Once optimistic revenue projections become accepted assumptions, organizations frequently expand rapidly.
Additional management layers are created.
Sales organizations grow.
Commercial support functions expand.
Every new hire increases fixed costs before revenue has been demonstrated.
When product adoption develops more slowly than expected, those costs become increasingly difficult to support.
This pattern is not unique to Marinus. It has occurred repeatedly throughout biotechnology over the past two decades.
Pipeline Expansion Is Never Guaranteed
Many investors viewed ganaxolone's long-term value as extending beyond its initial approval into additional neurological indications.
One of the company's most significant development opportunities was Status Epilepticus.
When that clinical program failed, the commercial outlook changed dramatically.
Future indications often justify today's commercial investment.
When those indications disappear, organizations may be left supporting infrastructure that was designed for a much larger company than current revenues can sustain.
Commercial Leadership Must Challenge Forecasts
One of commercial leadership's most important responsibilities is not simply executing launch plans.
It is challenging assumptions.
Leadership should continually ask difficult questions.
- What if diagnosis is slower than expected?
- What if physician adoption takes longer?
- What if payer access is delayed?
- What if only half the projected patients ultimately receive therapy?
- Can the organization remain financially sustainable under those conditions?
Conservative forecasting is rarely the most popular approach.
It is often the one that best protects long-term shareholder value.
Lessons for Biotechnology CEOs
Marinus offers several important commercialization lessons.
- Forecast conservatively. Base commercial planning on treated patients rather than disease prevalence.
- Scale organizations gradually. Commercial infrastructure should follow demonstrated demand—not anticipated demand.
- Stress-test assumptions. Every commercial forecast should include realistic downside scenarios.
- Protect capital. Every commercial investment should be supported by measurable market evidence.
- Diversify risk. Whenever possible, biotechnology companies should avoid relying on a single commercial asset to support the entire organization.
Final Thoughts
Marinus should be remembered as a reminder that commercial strategy deserves the same discipline as clinical development.
The company's experience demonstrates that commercialization decisions made years before launch can significantly influence long-term business outcomes.
Science creates possibility.
Clinical development demonstrates efficacy.
Commercial strategy determines whether innovation ultimately reaches patients while creating lasting value for investors, employees, and the company itself.
For biotechnology leaders, the most valuable lesson is not whether one company succeeded or failed. It is recognizing that disciplined commercial planning, realistic forecasting, and thoughtful capital allocation remain just as essential to long-term success as scientific innovation.
